Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) is now available.
Beijing Biostar Pharmaceuticals Co., Ltd. has announced its Annual General Meeting (AGM) scheduled for August 25, 2025, where key resolutions will be discussed. These include approving the financial statements and reports for 2024, determining remuneration packages for directors and supervisors, and appointing a new auditor. Additionally, a special resolution will be considered to authorize the repurchase of up to 10% of the company’s H Shares, reflecting strategic financial management and potential implications for capital market positioning.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and production of biological and chemical drugs, targeting various market segments within the healthcare sector.
Average Trading Volume: 1,140,900
Technical Sentiment Signal: Hold
Find detailed analytics on 2563 stock on TipRanks’ Stock Analysis page.